This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Berrington de Gonzalez, A. Articles by Jee, S. H. PubMed PubMed Citation Articles by Berrington de Gonzalez, A. Articles by Jee, S. H.

Pancreatic Cancer and Factors Associated with the Insulin Resistance Syndrome in the Korean Cancer Prevention Study

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health; ² Department of Oncology and Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, Maryland; ³ Department of Epidemiology and Health Promotion, and ⁴ Institute for Health Promotion, Graduate School of Public Health, Yonsei University; ⁵ National Health Insurance Corporation, Seoul, Korea; and ⁶ Department of Health Policy and Management, College of Medicine, Cheju National University, Cheju, Korea

Requests for reprints: Sun Ha Jee, Department of Epidemiology and Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea. Phone: 82-17-209-5095; Fax: 82-2-365-5118. E-mail: jsunha{at}yumc.yonsei.ac.kr

There is increasing evidence that type 2 diabetes mellitus and glucose intolerance are a cause, not just a consequence, of pancreatic cancer. We examined whether other factors that characterize the insulin resistance syndrome are also risk factors for pancreatic cancer in a prospective cohort study of 631,172 men and women (ages 45+ years) who received health insurance from the Korean Medical Insurance Corporation. The biennial medical evaluations from 1992 to 1995 provided the baseline information for this study. Relative risks (RR) were estimated using proportional hazards models adjusted for age, sex, smoking, and fasting serum glucose (after excluding the first 2 years of follow-up). There were 2,194 incident cases of pancreatic cancer diagnosed in the cohort over a median follow-up of 12 years. There was no evidence that pancreatic cancer risk was associated with total cholesterol, systolic blood pressure, WBC count, or body mass index. Abnormal levels of aspartate aminotransferase and alanine aminotransferase were both associated with a moderately increased risk of developing the disease (40+ versus <20; RR, 1.33; 95% CI, 1.14-1.55; P_trend = 0.05 and RR, 1.34; 95% CI, 1.16-1.56; P_trend = 0.02, respectively). Excluding 6 years of follow-up reduced this RR (95% CI) for aspartate aminotransferase to 1.22 (1.01-1.49), but even after excluding 10 years follow-up the RR (95% CI) for alanine aminotransferase was unchanged [1.36 (1.01-1.83)]. Although fasting serum glucose has been found previously to be associated with pancreatic cancer risk in this cohort, most other factors that characterize insulin resistance syndrome were not associated with pancreatic cancer risk. The association with elevated liver enzyme levels is a novel finding that warrants further investigation. (Cancer Epidemiol Biomarkers Prev 2008;17(2):359–64)